ArticleAmerican journal of preventive medicine2022
Racial‒Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid.
Article in American journal of preventive medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Evidence-based framework for identifying opioid use disorder in administrative data: A systematic review and methodological development study.Pain medicine (Malden, Mass.) · 2026Pooled it
- Community-level determinants of buprenorphine provider availability: A ZCTA-level (zip code tabulation area) analysis.Drug and alcohol dependence reports · 2026Article
- Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations.Journal of general internal medicine · 2026Article
- Buprenorphine prescribing is increasingly delivered by primary care nurse practitioners to Medicaid beneficiaries.Journal of the American Association of Nurse Practitioners · 2026Article
- Statewide trends in access to medications for opioid use disorder (moud) among adolescents with opioid use disorders in Indiana.Drug and alcohol dependence reports · 2026Article
- Article
- Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries.The American journal of drug and alcohol abuse · 2026Article
- Differential Changes in Use of Medications for Opioid Use Disorder by Race-Ethnicity: Effects of a Hub-and-Spoke Model.Psychiatric services (Washington, D.C.) · 2025Article
- Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder by Race and Ethnicity and Insurance Type.JAMA network open · 2025Article
- Medicaid Patients With ED Visits For Overdose: Disparities In Initiation Of Medications For Opioid Use Disorder.Health affairs (Project Hope) · 2025Article
- Racial/ethnic inequality in homelessness and drug overdose deaths in US States.Social psychiatry and psychiatric epidemiology · 2025Article
- A Scoping Review of the Utilization of Opioid Use Treatment, Harm Reduction, and Culturally Tailored Interventions Among Racial/Ethnic Minorities in the United States.International journal of mental health and addiction · 2025Article
- Advancing research translation in addiction and pain: A portfolio analysis of the NIH HEAL initiative.Journal of clinical and translational science · 2025Article
- Article
- Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study.Journal of substance use and addiction treatment · 2024Article
- Multilevel Factors Impacting Substance Use Treatment Access, Engagement, and Racial Equity Among Opioid Overdose Survivors in Boston, MA.Journal of general internal medicine · 2024Article
- Association of economic and racial segregation with restricted buprenorphine dispensing in U.S. community pharmacies.Drug and alcohol dependence reports · 2024Article
- Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements.JAMA network open · 2024Article
- Association between claims-based setting of diagnosis and treatment initiation among Medicare patients with hepatitis C.Health services research · 2024Article
- Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.Harm reduction journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
introductionExpanding access to medications for opioid use disorder is a cornerstone to addressing the opioid overdose epidemic. However, recent research suggests that the distribution of medications for opioid use disorder has been inequitable. This study analyzes the racial‒ethnic disparities in the receipt of medications for opioid use disorder among Medicaid patients diagnosed with opioid use disorder.
methodsMedicaid claims data from the Transformed Medicaid Statistical Information System for the years 2017-2019 were used for the analysis. Logistic regression models estimated the odds of receiving buprenorphine and Vivitrol within 180 days after initial opioid use disorder diagnosis on the basis of race‒ethnicity. Analysis was conducted in 2022.
resultsNon-Hispanic Black people, non-Hispanic American Indian or Alaskan Native/Asian/Hawaiian/Pacific Islander people, and Hispanic people had 42%, 12%, and 22% lower odds of buprenorphine receipt and 47%, 12%, and 20% lower odds of Vivitrol receipt, respectively, than non-Hispanic White people, controlling for clinical and demographic patient variables.
conclusionsThis study suggests that there are racial‒ethnic disparities in the receipt of buprenorphine and Vivitrol among Medicaid patients diagnosed with opioid use disorder after adjusting for demographic, geographic, and clinical characteristics. The potential strategies to address these disparities include expanding the workforce of providers who can prescribe medications for opioid use disorder in low-income communities and communities of color and allocating resources to address the stigma in medications for opioid use disorder treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.